戻る Agenda
Session 3: Lifecycle Management – Walking Towards Harmonized and Efficient Procedures to Manage Post-Approval Changes in Benefit of Patients
Session Chair(s)
Susan Koepke, MBA
Head of Regulatory Affairs LATAM
EMD Serono, Inc., United States
The session will be composed by two presentations about WHO guidelines on procedures and data requirements for changes to approved biotherapeutics from WHO and Health Canada, to explain the content of the guideline and how to use it from regulatory body point of view. To complement the session, an industry representative will bring case studies using WHO guidelines on procedures and data requirements for changes to approved biotherapeutics and other complementary guidelines as per ICH Q12.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Apply WHO guidelines on procedures and data requirements for changes to approved biotherapeutics in a work basis
- Identify opportunities to achieve harmonized and efficient procedures to manage post-approval changes in benefit of patients
- Develop regulatory risk and science-based strategies for post-approval changes putting patients at the center of the decision
Speaker(s)
How to Apply WHO Guidelines on Procedures and Data Requirements for Changes to Approved Biotherapeutics
Hugo Hamel, MBA, MSc
Health Canada, Canada
Associate Director, BRDD
Cases Studies to Apply WHO Guidelines on Procedures and Data Requirements for Changes to Approved Biotherapeutics and ICH Q12
Omar Ruiz
Pfizer, United States
Sr. Director Regulatory Affairs
Speaker
Patricia Aprea, MD
ANMAT, Argentina
Director, Evaluation and Control of Biológicals/Research
Panelist
Renata De Lima Soares
Anvisa, Brazil
Regulation and Health Surveillance Specialist